Prime Therapeutics administers prescription drug benefits and is a diversified pharmacy solutions organization serving health plans, employers and government programs. It is owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management, one of their companies, serves public sector state government programs. According to a press release issued today, on July 11, Prime/Magellan Rx discovered unauthorized access to an employee’s mobile email account. The notification does not state when the access first occurred or how the threat actor gained that access, but only when they discovered it. “That email account contained documents that included members’ personal health information, including name, address, date of birth, member ID number and medication(s),” they write, adding, “Prime has obtained no evidence to indicate that the information involved in this incident was actually accessed or has been misused.” You can read the full press release at Yahoo!
Prime Therapeutics administers prescription drug benefits and is a diversified pharmacy solutions organization serving health plans, employers and government programs. It is owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management, one of their companies, serves public sector state government programs. According to a press release issued today, on July 11, Prime/Magellan Rx discovered unauthorized access to an employee’s mobile email account. The notification does not state when the access first occurred or how the threat actor gained that access, but only when they discovered it. “That email account contained documents that included members’ personal health information, including name, address, date of birth, member ID number and medication(s),” they write, adding, “Prime has obtained no evidence to indicate that the information involved in this incident was actually accessed or has been misused.” You can read the full press release at Yahoo!
https://www.databreaches.net/prime-therapeutics-magellan-rx-discloses-hipaa-breach/